MEDTRONIC CAPSURE EPI EPICARDIAL STEROID-ELUTING PACING LEAD APPROVABLE WITH CONDITIONS, PANEL FINDS; POSTMARKET STUDY OF 50-60 ADULTS RECOMMENDED
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's CapSure EPI epicardial steroid-eluting pacing lead is approvable with conditions for adult and pediatric patients in whom transvenous leads cannot be used, FDA's Circulatory System Devices Panel concluded at a July 15 meeting in Rockville, Maryland. The panel agreed that the lead (model 4965) can be used for bradycardia pacing in pediatric patients with anatomy too small to accommodate transvenous leads and in adults with conditions that preclude access with a transvenous system.
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.